Research demonstrates potential of biomarker-driven immunotherapy strategies for sepsis, indicating improvement in patient outcomes.
Successful translation of checkpoint-based immunotherapies requires precision medicine frameworks matching the right intervention to the right patient at the right time. Combination immunotherapies hold promise when guided by biomarker-driven stratification.
No takes yet. Share an insight, caveat, or question.
Abbas et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: